Figure 1.

The ALLTogether MRD-based, mixed risk stratification system for risk-oriented therapy in patients with Ph− ALL 1–45 years. The master trial consisted of chemotherapy (chemo) of increasing intensity for SR, IR and HR patients, respectively, along with other risk-specific randomized or non-randomized interventions as indicated. TKI denotes tyrosine kinase inhibitor (imatinib) for cases with ABL-class fusions and CAR-T and BCP denote chimeric antigen receptor T-cell therapy and B-cell precursor ALL, respectively.